{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}],"title":"locoregional control"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}],"title":"progress-free survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"overall survival rates"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"long term toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates.","groups":[{"description":"Recommended dose of celecoxib was 400mg","id":"OG000","title":"Erlotinib + Celecoxib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity","type":"SECONDARY","unitOfMeasure":"percentage of participants"}